Naive Pluripotent Stem Cell Culture Medium for Stable Reprogramming
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for generating induced pluripotent stem cells (iPSCs) suffer from low reprogramming efficiency and stochastic outcomes, with conventional human ESCs and iPSCs exhibiting compromised pluripotency and high differentiation propensity, and the conditions for deriving authentic naive pluripotent stem cells in humans remain undefined.
Innovation Solution
The development of a culture medium comprising specific inhibitors (ERK1/2, GSK3β, p38, JNK, STAT3 activators) and growth factors (LIF, bFGF, TGFβ1) supports the generation and maintenance of naive pluripotent stem cells, characterized by unmethylated XIST and high TFE3 nucleus-to-cytoplasm expression ratio, maintaining pluripotency and stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional reprogramming methods using OSKM transcription factors are applied, then iPSCs can be generated from somatic cells, but reprogramming efficiency remains low (up to 0.1-20%) and outcomes are highly stochastic
Solution Approach 1:
The patent applies parameter changes by modifying the reprogramming protocol to include specific small molecule inhibitors (PD0325901 for ERK1/2, CHIR99021 for GSK3β) and cytokines (LIF, SCF, bFGF, TGFβ1) in combination with OSKM factors. This chemical parameter modification transforms the stochastic reprogramming process into a more controlled and efficient process, achieving high reprogramming efficiency while maintaining consistency across different somatic cell types
Solution Approach 2:
The patent introduces intermediary substances (small molecule inhibitors and cytokines) that mediate between the reprogramming factors and the somatic cells. These intermediaries facilitate chromatin remodeling and signaling pathway modulation, enabling more reliable and efficient reprogramming by acting as bridges that enhance the impact of OSKM factors on target genes
2Reliability
If conventional human ESCs and iPSCs are used, then pluripotent cells can be obtained, but they exhibit compromised pluripotency and high differentiation propensity
Solution Approach 1:
The patent applies preliminary anti-action by pre-treating cells with differentiation inhibitors (PD0325901, CHIR99021) and growth factors (LIF, SCF, bFGF, TGFβ1) before introducing reprogramming factors. This preliminary treatment establishes a protective state that prevents premature differentiation and maintains pluripotency throughout the reprogramming process and subsequent culture passages
Solution Approach 2:
The patent uses a composite approach by combining multiple reprogramming factors (OSKM), small molecule inhibitors (PD0325901, CHIR99021), and cytokines (LIF, SCF, bFGF, TGFβ1) into a single integrated reprogramming protocol. This composite protocol synergistically enhances pluripotency stability and prevents differentiation, producing iPSCs with consistent and reliable pluripotent characteristics
3Productivity
If extensive cell proliferation is required for reprogramming, then iPSC conversion can be achieved, but the process takes at least one week and follows an unpredictable time latency pattern
Solution Approach 1:
The patent applies preliminary action by pre-conditioning somatic cells with differentiation inhibitors and growth factors before reprogramming factor introduction. This preliminary preparation accelerates subsequent reprogramming by pre-opening chromatin structures and activating relevant signaling pathways, reducing the overall reprogramming time from one week to several days while maintaining high efficiency
Solution Approach 2:
The patent implements periodic action through staged reprogramming protocols where reprogramming factors are introduced in multiple rounds at different time points, with intermediate assessments and adjustments. This periodic approach optimizes the reprogramming trajectory, accelerating the process by identifying and addressing rate-limiting steps at different stages
Data Source
AI summary
Provided is an isolated human naive pluripotent stem cell (PSC), wherein: (i) when the naive PSC is a female PSC, then said naive female PSC has two unmethylated alleles of an X-inactive specific transcript (XIST) gene; and (ii) when said naive PSC is a male PSC, then said naive male PSC has an unmethylated allele of said XIST gene. Also provided is a culture medium which comprises an ERK1/2 inhibitor, a GSK3beta inhibitor, a p38 inhibitor, a JNK inhibitor, a STAT3 activator and at least one agent selected from the group consisting of: bFGF, TGFbeta 1, a PKC inhibitor, a ROCK inhibitor and a NOTCH inhibitor; or at least agent selected from the group consisting of: a TGFR inhibitor, a FGFR inhibitor, a PKC inhibitor, a ROCK inhibitor and a NOTCH inhibitor.